U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07227948) titled 'Repurposing Semaglutide for the Treatment of Cocaine Use Disorder' on Nov. 10.
Brief Summary: The purpose of this study is to evaluate semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in combination with cognitive behavioral therapy (CBT) for the treatment of cocaine use disorder (CUD).
Study Start Date: Nov. 17
Study Type: INTERVENTIONAL
Condition:
Cocaine Use Disorder
Intervention:
DRUG: Semaglutide
Participants will receive 14 weekly injections administered subcutaneously. Semaglutide will be initiated at a dose of 0.25 mg once weekly. After 4 weeks, the dose will be increased to 0.5 mg once weekly for an...